BJU International最新文献

筛选
英文 中文
Real-world use of androgen-deprivation therapy intensification for metastatic hormone-sensitive prostate cancer: a systematic review 雄激素剥夺疗法强化治疗转移性激素敏感性前列腺癌的实际应用:系统综述
IF 4.5 2区 医学
BJU International Pub Date : 2024-11-12 DOI: 10.1111/bju.16577
Amit D. Raval, Stephanie Chen, Natasha Littleton, Niculae Constantinovici, Peter J. Goebell
{"title":"Real-world use of androgen-deprivation therapy intensification for metastatic hormone-sensitive prostate cancer: a systematic review","authors":"Amit D. Raval, Stephanie Chen, Natasha Littleton, Niculae Constantinovici, Peter J. Goebell","doi":"10.1111/bju.16577","DOIUrl":"https://doi.org/10.1111/bju.16577","url":null,"abstract":"To conduct a systematic literature review of real-world data (RWD) studies to summarise treatment patterns among men with metastatic hormone-sensitive prostate cancer (mHSPC). While androgen-deprivation therapy (ADT) is a primary treatment strategy for mHSPC, ADT intensification with androgen receptor pathway inhibitors (ARPIs) and/or chemotherapy is recommended by current guidelines and has improved clinical outcomes in the last decade.","PeriodicalId":8985,"journal":{"name":"BJU International","volume":"196 1","pages":""},"PeriodicalIF":4.5,"publicationDate":"2024-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142599922","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evaluating the efficacy of physiotherapy in post-prostatectomy continence and pelvic muscle function 评估物理治疗对前列腺切除术后尿失禁和骨盆肌肉功能的疗效
IF 4.5 2区 医学
BJU International Pub Date : 2024-11-12 DOI: 10.1111/bju.16591
Wei-Zhen Tang, Wei-Ze Xu, Tai-Hang Liu
{"title":"Evaluating the efficacy of physiotherapy in post-prostatectomy continence and pelvic muscle function","authors":"Wei-Zhen Tang, Wei-Ze Xu, Tai-Hang Liu","doi":"10.1111/bju.16591","DOIUrl":"https://doi.org/10.1111/bju.16591","url":null,"abstract":"Click on the article title to read more.","PeriodicalId":8985,"journal":{"name":"BJU International","volume":"158 1","pages":""},"PeriodicalIF":4.5,"publicationDate":"2024-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142601969","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Urogeriatrics: a critical perspective for future urologists 泌尿老年病学:未来泌尿科医生的重要视角
IF 4.5 2区 医学
BJU International Pub Date : 2024-11-11 DOI: 10.1111/bju.16587
William C. Gibcus, Anne Hong, David C. Chen, Henry C.X. Yao, Anthony Ta, Marlon Perera, Joseph J. Ischia, Damien M. Bolton
{"title":"Urogeriatrics: a critical perspective for future urologists","authors":"William C. Gibcus, Anne Hong, David C. Chen, Henry C.X. Yao, Anthony Ta, Marlon Perera, Joseph J. Ischia, Damien M. Bolton","doi":"10.1111/bju.16587","DOIUrl":"https://doi.org/10.1111/bju.16587","url":null,"abstract":"","PeriodicalId":8985,"journal":{"name":"BJU International","volume":"31 1","pages":""},"PeriodicalIF":4.5,"publicationDate":"2024-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142599411","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Lower pole stones 1–2 cm: navigating treatment choices 下极结石 1-2 厘米:治疗选择导航
IF 4.5 2区 医学
BJU International Pub Date : 2024-11-11 DOI: 10.1111/bju.16589
Carlotta Nedbal, Bhaskar K. Somani
{"title":"Lower pole stones 1–2 cm: navigating treatment choices","authors":"Carlotta Nedbal, Bhaskar K. Somani","doi":"10.1111/bju.16589","DOIUrl":"https://doi.org/10.1111/bju.16589","url":null,"abstract":"<p>Lower-pole renal stones might represent a challenge in endoscopic treatment, especially for intermediate sizes (1–2 cm), that come with no strong indication or contraindication for one technique over the other [<span>1</span>]. The sharp infundibulopelvic angle, together with the infudibulopelvic width and length, often determine treatment choices, along with the available expertise, cost and patient choice. On the other hand, some might argue that it would be excessive to perform a percutaneous nephrolithotomy (PCNL) for intermediate stone sizes, when other technologies such as flexible ureteroscopy (f-URS) allow for a lesser invasive approach. One of the most frequently applied strategies to treat intermediate-size lower-pole stones is to relocate them in the upper pole or in the renal pelvis. Despite it being a feasible and efficient technique, stone relocation might sometimes be uneasy due to the stone size or the infundibulopelvic angle, prolonging the operative times.</p>\u0000<p>In a recent prospective randomised trial, Elmansy et al. [<span>1</span>] compared the outcomes between f-URS and laser lithotripsy (f-URSL) and miniaturised PCNL (mini-PCNL) for these intermediate lower-pole stones without relocation. The most interesting finding of the study is indeed on the important difference in reported stone-free rates (SFRs). They found a 1-day SFR of 50% in the mini-PCNL group vs only 11.1% in the f-URSL group, increasing to 72.2% in the mini-PCNL and to 37.1% in the f-URSL group at 90-days follow-up. When including fragments up to 2 mm, the 3-month SFR rose in fact to 86.1% and 71.4% for mini-PCNL and f-URSL, respectively. Recent data from Brian et al. [<span>2</span>] show that over 50 months, residual fragments >4 mm have a disease progression rate of up to 88% and intervention rate of up to 47%.</p>\u0000<p>Indeed, the difference between mini-PCNL and f-URSL reported by Elmansy et al. [<span>1</span>] is significant, favouring the percutaneous treatment [<span>1</span>]. These findings are in line with the literature, reporting higher SFR for PCNL compared to classic f-URSL [<span>3</span>]. In a recent review on 1–2 cm lower-pole stones, mini-PCNL showed in fact higher efficacy in complete stone clearance, while demonstrating comparable complications rates and operative times. The difficult position and manoeuvrability of the retrograde access could be addressed as the main limitation for treating this kind of calculi, reaching lower SFRs than the ones usually reported for stones located in medium/upper renal calyces. At the same time, mini-PCNL has shown good safety profiles, at least partially overcoming the classic limitations of the percutaneous access, namely the high bleeding risk and the need for a postoperative nephrostomy. In their study, Elmansy et al. [<span>1</span>] reported a low bleeding risk during the puncture (7.4%), and good triangulation outcomes avoiding the need for multiple punctures. They also aimed for totally tub","PeriodicalId":8985,"journal":{"name":"BJU International","volume":"10 1","pages":""},"PeriodicalIF":4.5,"publicationDate":"2024-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142599913","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
MUC Abstracts 市政大会摘要
IF 3.7 2区 医学
BJU International Pub Date : 2024-11-11 DOI: 10.1111/bju.16560
{"title":"MUC Abstracts","authors":"","doi":"10.1111/bju.16560","DOIUrl":"10.1111/bju.16560","url":null,"abstract":"","PeriodicalId":8985,"journal":{"name":"BJU International","volume":"134 S1","pages":"4-41"},"PeriodicalIF":3.7,"publicationDate":"2024-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/bju.16560","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142599407","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The European Association of Urology talent incubator: bridging competencies for holistic urological care 欧洲泌尿外科协会人才孵化器:为泌尿外科整体护理搭建能力桥梁
IF 4.5 2区 医学
BJU International Pub Date : 2024-11-09 DOI: 10.1111/bju.16586
Fabian P. Stangl, Juan Luis Vásquez
{"title":"The European Association of Urology talent incubator: bridging competencies for holistic urological care","authors":"Fabian P. Stangl, Juan Luis Vásquez","doi":"10.1111/bju.16586","DOIUrl":"https://doi.org/10.1111/bju.16586","url":null,"abstract":"Click on the article title to read more.","PeriodicalId":8985,"journal":{"name":"BJU International","volume":"151 1","pages":""},"PeriodicalIF":4.5,"publicationDate":"2024-11-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142598091","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Adjuvant immunotherapy for high‐risk renal cell carcinoma—now or never? 高危肾细胞癌的辅助免疫疗法--现在还是永远?
IF 4.5 2区 医学
BJU International Pub Date : 2024-11-08 DOI: 10.1111/bju.16584
Tivya Kulasegaran, Niara Oliveira, Craig Gedye, Shomik Sengupta
{"title":"Adjuvant immunotherapy for high‐risk renal cell carcinoma—now or never?","authors":"Tivya Kulasegaran, Niara Oliveira, Craig Gedye, Shomik Sengupta","doi":"10.1111/bju.16584","DOIUrl":"https://doi.org/10.1111/bju.16584","url":null,"abstract":"Click on the article title to read more.","PeriodicalId":8985,"journal":{"name":"BJU International","volume":"196 1","pages":""},"PeriodicalIF":4.5,"publicationDate":"2024-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142597142","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The first step in shared decision-making for prostate cancer screening. 前列腺癌筛查共同决策的第一步。
IF 3.7 2区 医学
BJU International Pub Date : 2024-11-06 DOI: 10.1111/bju.16580
Takeshi Takahashi
{"title":"The first step in shared decision-making for prostate cancer screening.","authors":"Takeshi Takahashi","doi":"10.1111/bju.16580","DOIUrl":"https://doi.org/10.1111/bju.16580","url":null,"abstract":"","PeriodicalId":8985,"journal":{"name":"BJU International","volume":" ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2024-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142590034","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The impact of progression-directed therapy on survival in metastatic castration-refractory prostate cancer: MEDCARE phase 3 trial. 进展导向疗法对转移性难治性前列腺癌患者生存期的影响:MEDCARE 3期试验。
IF 3.7 2区 医学
BJU International Pub Date : 2024-11-06 DOI: 10.1111/bju.16574
Kato Rans, Karolien Goffin, Steven Joniau, Gedske Daugaard, Julie den Hartog, Lodewijk Van Wynsberge, Gert De Meerleer
{"title":"The impact of progression-directed therapy on survival in metastatic castration-refractory prostate cancer: MEDCARE phase 3 trial.","authors":"Kato Rans, Karolien Goffin, Steven Joniau, Gedske Daugaard, Julie den Hartog, Lodewijk Van Wynsberge, Gert De Meerleer","doi":"10.1111/bju.16574","DOIUrl":"10.1111/bju.16574","url":null,"abstract":"<p><strong>Background: </strong>Metastatic castration-refractory prostate cancer (mCRPC) presents a therapeutic challenge despite advancements in treatment. Once mCRPC is attained, patients face limited survival prospects. Next-line systemic treatment (NEST) is the standard of care for progressive mCRPC, encompassing various therapeutic options with associated toxicity and costs. In patients with oligoprogressive mCRPC, data suggest that progression-directed therapy (PDT), such as metastasectomy or stereotactic body radiotherapy, delays the initiation of NEST.</p><p><strong>Methods and design: </strong>The MEDCARE phase III trial aims to assess the impact of PDT on overall survival (OS) in oligoprogressive mCRPC. In this multicentric, randomised, prospective trial, we aim to randomise 246 patients in 1:1 allocation ratio between the standard-of-care therapy (surveillance or NEST) or PDT while continuing the current systemic treatment. Patients will be stratified based on number of progressive lesions (one vs ≥one), location of progressive lesions (local recurrence, N or M1a vs M1b or M1c) and previous systemic therapy (palliative androgen-deprivation therapy [pADT] vs pADT + androgen receptor-targeted agent or patients who received docetaxel in the past). The primary endpoint is OS, and the secondary endpoints include quality of life, radiographic progression-free survival (PFS), modified PFS, prostate cancer-specific survival and PDT-induced toxicity.</p><p><strong>Discussion: </strong>This is the first randomised phase 3 trial in the setting of PDT in patients with oligoprogressive mCRPC with OS as the primary endpoint.</p>","PeriodicalId":8985,"journal":{"name":"BJU International","volume":" ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2024-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142590035","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Response to Takahashi. 回应高桥。
IF 3.7 2区 医学
BJU International Pub Date : 2024-11-06 DOI: 10.1111/bju.16581
Zen Yang Ang, Yuke-Lin Kong, Zarith Nameyrra Md Nesran, Shaun Wen Huey Lee
{"title":"Response to Takahashi.","authors":"Zen Yang Ang, Yuke-Lin Kong, Zarith Nameyrra Md Nesran, Shaun Wen Huey Lee","doi":"10.1111/bju.16581","DOIUrl":"https://doi.org/10.1111/bju.16581","url":null,"abstract":"","PeriodicalId":8985,"journal":{"name":"BJU International","volume":" ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2024-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142590029","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信